Skip to main content

Olon to open US HPAPI suite

Italian CDMO Olon Group has announces the ongoing construction of a high potency API (HPAPI) suite at the site in Concord, Ohio, which hosts its centre of excellence for early development of APIs. This adds to the commercial-scale capabilities of sites at Segrate and Rodano, near Milan, Italy, where Olon has invested about €40 million in the last few years.

Olon opens R&D centre

Italian CDMO Olon has opened its new R&D centre at its industrial plant and headquarters in Rodano, near Milan. This will be mainly dedicated to the development of APIs for the innovator and generic markets. It cost €10 million and will create 50 new jobs, bringing the total to 350 out of the 2,300 total.

Olon to expand Indian site

Italian CDMO Olon Group has announced a €10 million, multi-year expansion plan for its production site in Mahad, India. This will increase its chemical synthesis capacity for intermediates and APIs by 45%, particularly for products in high demand where Olon is already the market leader.

Olon to build ADC payloads facility

Italian CDMO Olon has announced the start of a construction on a €22 million facility for the production of ultra-potent compounds. These are aimed for use mainly as payloads and payload-linkers for antibody-drug conjugates (ADCs) at its site at Rodano, near Milan. The facility will reach containment OEB Level 6, with a target occupational exposure level (OEL) of 10 ng/m3.

Olon presents biotech plan

Italian CDMO and API supplier Olon has presented a two-year, €30 million plan to expand its Settimo Torinese Biotech Hub near Turin. This focuses on microbial fermentation and is claimed to have “some of the most extensive know-how” on the subject in Europe”. The plan focuses on therapeutic peptides based on Olon’s expertise in the development of rDNA peptides and proteins.

Olon Biotech division launched

Italian firm Olon has presented its new division, Olon Biotech, which will offer CDMO services at industrial scale. These based on microbial fermentation processes using bacteria, yeast and fungi and will include high potency. It will also have proprietary products for industries including health and pharma, food, cosmetics, flavours and fragrances.

Olon begins R&D centre

Italian CDMO Olon is to invest €10 million to create an R&D hub at its headquarters site at Rodano near Milan. This will integrate seven existing R&D centres and will be dedicated entirely to research laboratories to be used to develop APIs and manufacturing processes. 

Construction has started and is due to be completed in Q2 2023. This will also lead to about 50 new researchers being hired, bringing the corporate total to around 350.

Subscribe to Olon